Semax

Semax is a synthetic Russian nootropic peptide, a fragment of ACTH(4-10) with a Pro-Gly-Pro tail added to strip out the hormonal activity of the parent molecule. It has been registered in Russia since the 1990s as a prescription nasal-drop drug and has real, published human clinical data behind it, all from Russian stroke-rehabilitation trials, none blinded or placebo-controlled by Western standards, and none independently replicated outside Russia. It is not approved anywhere outside Russia, and the cognitive-enhancement doses circulating online are roughly a tenth of the doses actually studied in stroke patients.

Ask about Semax

Research snapshot

Peptide categorySynthetic heptapeptide, ACTH(4-10) fragment analogue with a Pro-Gly-Pro stabilizing tail
Primary research interestPost-stroke motor and functional recovery (adjunct to rehabilitation); popularly used off-label as a cognitive-enhancement nootropic
Highest available evidencePublished human clinical studies (Russian stroke-rehabilitation trials), but none blinded or placebo-controlled by Western standards, and none independently replicated outside Russia
Human research availableYes, in post-stroke rehabilitation only, not in healthy volunteers for cognitive enhancement
Development statusLong-registered Russian prescription drug since the 1990s; never submitted for approval elsewhere
Regulatory statusRegistered as a prescription drug in Russia only; no FDA, EMA, or other major regulatory approval; named in a draft HHS 503A enforcement-discretion policy published 30 Oct 2026 (not approval)

Technical identity

Primary nameSemax
Alternative namesSemax 0.1%; Semax 1%; ACTH(4-10) analogue
Peptide sequenceMet-Glu-His-Phe-Pro-Gly-Pro
Amino-acid length7 residues
Molecular formulaNot independently re-verified in this research pass
Molecular weightNot independently re-verified in this research pass
CAS Registry Number80714-61-0, as commonly cited in the literature and on vendor material; not independently re-derived for this entry
PubChem CIDNot independently re-verified in this research pass
UNIINot established
DrugBank IDNot established
Chemical modificationsACTH(4-7) fragment with a Pro-Gly-Pro tripeptide appended to the C-terminus, removing the hormonal/adrenal-stimulating activity of the parent molecule
Peptide classACTH-fragment-derived heptapeptide
Primary biological targetNot conclusively established: proposed to act via the BDNF (brain-derived neurotrophic factor) system rather than the classical ACTH receptor pathway
Developer or originatorInstitute of Molecular Genetics, Moscow (developed in the Soviet Union in the 1980s)
Development statusRegistered prescription drug in Russia; no FDA/EMA development pathway

What it is

Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, built from the first four residues of ACTH(4-10) with a Pro-Gly-Pro tripeptide added to the end. It was developed in the Soviet Union in the 1980s at what is now the Institute of Molecular Genetics in Moscow, and it is registered in Russia as a prescription nootropic drug, sold as intranasal drops. It has never been submitted for approval in the United States, the European Union, or any other major regulatory jurisdiction, and it has no FDA label, no EMA authorisation and no INN.

It is not thought to act through the classical ACTH receptor pathway that governs cortisol release; the Pro-Gly-Pro addition and truncation are specifically what removed the hormonal, adrenal-stimulating activity of the parent ACTH fragment while research groups reported retaining central nervous system effects. It is usually described as acting on the BDNF (brain-derived neurotrophic factor) system, though the mechanism is not settled.

Potential benefits and research applications

Post-stroke motor and functional recovery, the one setting with real human trials

Semax has been studied specifically as an adjunct in acute ischemic stroke and post-stroke rehabilitation, where Russian trials have reported improved clinical rating scale scores, higher plasma BDNF, and better Barthel index (functional independence) outcomes in patients who also received standard rehabilitation care. This is the only context in which Semax has published human clinical data behind it.

Evidence: human, non-blinded and non-placebo-controlled (Tier 2, human observational/registered-trial-equivalent evidence, not Tier 1). The trials compared Semax plus standard care against standard care alone, so the specific contribution of Semax cannot be isolated with confidence, and none has been repeated outside Russia.

Cognitive enhancement, focus and memory in healthy people, a claim built on a different population than the one actually studied

Semax is marketed and discussed online almost entirely as a nootropic for healthy people seeking sharper focus, faster recall or reduced mental fatigue. This use case is extrapolated from Semax’s proposed BDNF-elevating mechanism and from rodent and cell-culture work, not from the stroke-rehabilitation trials, which enrolled only acutely ill stroke patients at doses several times higher than what circulates for cognitive use.

Evidence: has been reported anecdotally among nootropic users; the mechanistic basis is theoretical/laboratory (Tier 4), and no human trial in a healthy, non-stroke population was located for this entry.

Neuroprotection and BDNF signaling, a plausible mechanism without a settled human dose-response

Preclinical and mechanistic work proposes that Semax raises brain-derived neurotrophic factor and related neurotrophic signaling, which is the leading explanation offered for both the stroke-recovery findings and the broader neuroprotection claims attached to the compound. Human data on this mechanism is limited to the biomarker measurements taken within the stroke trials themselves.

Evidence: is being investigated for a neurotrophic/neuroprotective role; supportive human biomarker data exists only within the stroke-trial context above, and a dedicated dose-response study in a non-stroke population has not been established.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
Acute hemispheric ischemic stroke (Gusev 1997)Intranasal12 mg/day (moderate stroke) or 18 mg/day (severe stroke)Daily5 to 10 daysPublished human research (Russian trial, not blinded or placebo-controlled)
Post-stroke rehabilitation (Gusev 2018)Intranasal6,000 mcg/dayDailyTwo 10-day courses, 20 days apartPublished human research (Russian trial, n=110, not blinded or placebo-controlled)
Cognitive/nootropic use, general (community)IntranasalCommonly reported as 300 to 1,000 mcg per dose, roughly a tenth of the stroke-trial dosesOne to three times dailyOften cycled, days to a few weeksCommunity / vendor reported: not studied in a clinical trial, and in a different population (healthy vs. acute stroke)

The human trial record

Semax has been given to human beings in published, Russian-language clinical studies, which sets it apart from most compounds on this site. That is worth stating plainly rather than treating the Russian literature as equivalent to nothing. It is also worth stating exactly what kind of trial record this is.

A 1997 study gave Semax to 30 patients in the acute phase of hemispheric ischemic stroke, compared against 80 patients on conventional therapy, and reported the most effective daily doses as 12 milligrams for moderate strokes and 18 milligrams for severe strokes, each over a 5- to 10-day course. A separate 1999 study examined immunobiochemical markers in the acute stroke period and reported a shift toward anti-inflammatory cytokine activity. A larger 2018 study followed 110 post-stroke patients through early or late rehabilitation, with or without Semax, using a standard regimen of 6,000 micrograms per day for two 10-day courses separated by a 20-day interval, and reported that Semax raised plasma BDNF and was associated with better Barthel index outcomes.

None of these three studies is a blinded, placebo-controlled trial by the standard this site applies elsewhere. The 1997 and 2018 studies compared a Semax group against a non-randomised control group receiving standard care, not a placebo; whether patients, clinicians or outcome assessors were blinded is not established in the material reviewed for this entry. The 1997 study is formally labelled a controlled clinical trial in its indexing, but that label does not by itself establish blinding or randomisation. Every one of these studies was conducted at Russian institutions, published only in Russian-language journals, and none has been independently replicated outside Russia in the sources located here.

No trial of Semax appears on ClinicalTrials.gov, and no independent Western replication of the stroke findings was located for this entry.

What is not established

Whether the cognitive-enhancement, mood, focus and neuroprotection claims attached to Semax in consumer material, most of which trace to rodent and cell-culture work rather than to the stroke trials above, hold up in a healthy human being taking it for those purposes. The published human trials are specifically in post-stroke rehabilitation, not in healthy volunteers seeking cognitive enhancement, and the two populations should not be treated as interchangeable.

Whether the stroke findings would replicate in a blinded, placebo-controlled design. No such trial was located.

Long-term human safety data outside the stroke-rehabilitation context. No dedicated human toxicology, drug-interaction or long-term-use study was located.

Regulatory status

Semax is registered in Russia as a prescription nasal-drop drug. It is not approved by FDA, the European Medicines Agency or any other major regulator outside Russia, and it has never been submitted for approval in those jurisdictions.

On 28 October 2026 HHS announced a draft enforcement discretion policy for compounding certain peptides under section 503A. It was published in the Federal Register on 30 October 2026 (91 FR 68526, docket HHS-OASH-2026-0496). Semax is one of six peptides named, listed as Semax free base, the unmodified heptapeptide and not an acetate or other modified form, with intranasal use only as the route in its Appendix B. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding it under 503A if conditions are met. These include a patient-specific prescription, one active ingredient per product, an ingredient from an FDA-registered CGMP manufacturer with a certificate of analysis showing the facility location, adverse event reporting, and the label “This is a compounded drug product. Not for resale.” The July 2026 Pharmacy Compounding Advisory Committee recommended it for the 503A bulks list. That vote is advice to FDA and is separate from this policy. It is a draft and is not binding on HHS or the public. It is not an FDA approval, it does not add Semax to the 503A bulks list, and it is not a rule. It does not bind state boards of pharmacy. HHS says it stays in place until each peptide is addressed in a final rule, and it can be withdrawn. It does not cover 503B outsourcing facilities. Comments close 13 November 2026. It adds no new human evidence, and the evidence assessment on this page is unchanged. The full analysis of the HHS policy covers all six peptides. For a plain-language report on the same policy, see The Weight Loss Atlas report on the HHS enforcement discretion policy, and for the dated sequence of decisions, its peptide policy tracker.

In its notes HHS says the intranasal human record compiled by its drug center covers several hundred subjects with no reported adverse outcome. That is HHS’s description, and this entry has not verified it against published papers. The human record this page can verify is the Russian stroke-rehabilitation literature described above, which was not blinded or placebo-controlled and has not been independently replicated outside Russia. Modified forms such as N-Acetyl Semax Amidate are different molecules and are not what the notice lists. The notice does not change the evidence assessment on this page. Our full analysis of the HHS policy covers all six peptides.

Frequently asked questions

What is Semax?

Semax is a synthetic heptapeptide derived from ACTH(4-10), developed in Russia in the 1980s and registered there as a prescription intranasal nootropic drug. It is not approved in the United States, the European Union or other major jurisdictions.

How does Semax work?

It is proposed to act by raising BDNF and related neurotrophic signaling rather than through the classical ACTH-cortisol pathway, though the exact receptor mechanism is not settled in the literature reviewed for this entry.

What dosage has been studied in humans?

Published Russian stroke trials used 12 to 18 milligrams per day intranasally over 5 to 10 days in one study, and 6,000 micrograms per day across two 10-day courses in another. These are far higher than the microgram-range doses discussed for cognitive use online.

What dosage commonly circulates online for cognitive use?

Community material typically describes 300 to 1,000 micrograms per dose, one to three times daily, often cycled for days to a few weeks. This is roughly a tenth of the doses used in the published stroke-rehabilitation trials and has not itself been studied in a clinical trial.

Has Semax been studied in humans?

Yes, in three published Russian stroke-rehabilitation studies. None was a blinded, placebo-controlled trial by Western standards, and none has been independently replicated outside Russia.

Is Semax approved for use?

It is registered as a prescription drug in Russia only. It has no FDA approval, EMA authorisation, or approval in any other major regulatory jurisdiction.

What routes of administration are reported?

Intranasal administration (nasal drops or spray) is the route used in every published human trial and in essentially all community-reported use.

Does Semax improve cognition in healthy people?

This has not been established. The published human trials studied post-stroke patients, not healthy volunteers, and no controlled human trial of Semax for cognitive enhancement in healthy people was located for this entry.

What side effects have been reported?

The stroke trials did not report a detailed adverse-event profile in the material reviewed here. Community reports describe nasal irritation and occasional anxiety or jitteriness at higher doses, but no dedicated human safety or toxicology study was located.

What remains unknown about Semax?

Whether the stroke-recovery findings would replicate in a blinded, placebo-controlled design; whether the cognitive-enhancement claims made for it in healthy people hold up under controlled testing; and its long-term safety profile outside the stroke-rehabilitation setting.

Bottom line

Semax stands out on this site for having real published human clinical data, three Russian stroke-rehabilitation studies reporting improved functional outcomes and higher plasma BDNF at doses of 12 to 18 milligrams per day. But none of these trials is blinded or placebo-controlled by Western standards, none has been replicated outside Russia, and none studied the healthy, cognitive-enhancement use case that drives most of the compound’s current popularity. The doses discussed online for that use are roughly a tenth of what has actually been studied, in a completely different population. Semax remains registered only in Russia, with no FDA, EMA or other major regulatory approval elsewhere.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
Cognitive/nootropic use, generalIntranasal300-1,000 mcg per dose (a few drops)One to three times dailyOften cycled, days to a few weeks

Circulating cognitive-enhancement material describes Semax at doses well below the stroke-trial figures above: typically a few hundred micrograms to about a milligram per dose, delivered as a few drops of a 0.1% or 1% intranasal solution, against the 12 to 18 milligrams per day used in the published stroke rehabilitation trials. The circulating figure is roughly an order of magnitude below what has actually been studied in a human being, and that human study was in acute stroke, not in a healthy person seeking a cognitive effect.

No circulating source reviewed for this entry cites the stroke trials by name or dose when presenting a cognitive-use figure, which means the two are not being knowingly scaled from one another; they simply coexist under the same compound name.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Research area: Neuro and cognitive.

Share thisFacebookXEmail